PF-04217903 methanesulfonate is primarily utilized in the field of biomedical research, particularly in the study of cancer therapies. It functions as a potent and selective inhibitor of c-Met kinase, which is a receptor tyrosine kinase involved in various cellular processes, including cell proliferation, survival, and motility. By inhibiting c-Met, this compound helps researchers investigate the pathways and mechanisms that drive tumor growth and metastasis, especially in cancers where c-Met signaling is dysregulated, such as certain types of lung, liver, and gastric cancers. Its application in preclinical studies aids in the development of targeted cancer treatments, offering insights into the efficacy and potential therapeutic strategies for c-Met-dependent malignancies. Additionally, it is used in pharmacological assays to evaluate the specificity and activity of c-Met inhibitors, contributing to the advancement of precision medicine in oncology.